Etiologic treatment of Chagas disease in Brazil

Our research group has experience in monitoring adverse reactions in Chagasdisease patients in treatment with benznidazole. This article was born out of needfor a review that incorporated different aspects pertaining to the etiologic treatmentof Chagas disease. To this end, a search of original arti...

Descripción completa

Detalles Bibliográficos
Autores: Oliveira, Maria de Fátima, Nagao-Dias, Aparecida T., Pontes, Vânia Maria Oliveira de, Souza Júnior, Alcidésio Sales de, Coelho, Helena Lutéscia Luna, Coelho, Ivo Castelo Branco
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2008
País:Brasil
Institución:Universidade Federal de Goiás (UFG)
Repositorio:Revista de patologia tropical (Online)
Idioma:portugués
OAI Identifier:oai:ojs.revistas.ufg.br:article/5063
Acceso en línea:https://revistas.ufg.br/iptsp/article/view/5063
Access Level:acceso abierto
Palabra clave:Treatment
Chagas disease
Drug adverse reactions
Benznidazole
Nifurtimox.
Tratamento etiológico
Doença de Chagas
Reações adversas a medicamentos
Benznidazol
Doenças Infecciosas e Parasitárias
Descripción
Sumario:Our research group has experience in monitoring adverse reactions in Chagasdisease patients in treatment with benznidazole. This article was born out of needfor a review that incorporated different aspects pertaining to the etiologic treatmentof Chagas disease. To this end, a search of original articles and revision papersindexed to Medline and Lilacs, and other publications related to the topic wasundertaken. Nifurtimox and benznidazole, two chemotherapeutic agents currentlyused in Chagas disease patients, have an efficacy higher than 80% in the acutephase, however only 8 to 30% in the chronic phase. The success of treatment maybe reduced due to various limitations of the currently available drugs, such asprolonged therapeutic scheme, adverse reactions and parasite genetic variability,including the existence of T. cruzi strains naturally resistant to these drugs. Thisreview reveals the necessity of development of new anti-T.cruzi drugs with lowertoxicity and higher effectiveness in the chronic phase.